Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Hepatoblastoma 1Fibrolamellar hepatocellular carcinoma 1Carcinoma, Hepatocellular 1

Interventions

X-Rays 7Specimen Handling 7Phantoms, Imaging 7Magnetic Resonance Spectroscopy 6Nuclear Medicine Department, Hospital 5Cyclophosphamide 5fludarabine 4Temozolomide 4Carboplatin 4Biopsy 4Oxaliplatin 3Nivolumab 3Melphalan 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vemurafenib 2Topotecan 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Whole-Body Irradiation × Gastrointestinal × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡